Noradrenalin Sintetica (Noradrenaline Tartrate)

Noradrenaline tartrate acts as a direct agonist at alpha‑adrenergic receptors, causing vasoconstriction and increasing systemic vascular resistance. It also stimulates beta‑1 receptors in the heart, enhancing contractility and cardiac output, which together support blood pressure and tissue perfusion.

The dosage of Noradrenalin Sintetica is individualized and set by the prescribing clinician based on the patient’s hemodynamic status, response to therapy, and clinical guidelines. Dosing is typically administered as an intravenous infusion that is titrated to effect.

The safety of Noradrenalin Sintetica in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Noradrenalin Sintetica is a first‑line vasopressor because of its strong alpha‑adrenergic activity combined with modest beta‑1 stimulation. Compared with agents such as dopamine or phenylephrine, it provides more predictable increases in blood pressure with less tachyarrhythmia risk, making it preferred in many critical‑care protocols.

The product should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep it in the original packaging to maintain stability until it is prepared for intravenous administration.

Noradrenalin Sintetica is supplied as an injectable solution for intravenous infusion. It is typically administered through a central venous catheter, with the infusion rate adjusted continuously based on the patient’s blood pressure and cardiac response.

Serious risks include severe hypertension, life‑threatening arrhythmias, myocardial ischemia, tissue necrosis from extravasation, and pulmonary edema. Continuous hemodynamic monitoring is essential to detect and manage these complications promptly.

Patients with known hypersensitivity to noradrenaline or its excipients, uncorrected pheochromocytoma, or those in whom severe vasoconstriction could cause harm (e.g., certain peripheral vascular diseases) should not receive this medication. Clinical judgment is required for each case.